Stockreport

Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma

Idera Pharmaceuticals, Inc.  (IDRA) 
Last idera pharmaceuticals, inc. earnings: 11/6 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.iderapharma.com/investor-overview
PDF – Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EX [Read more]